Advertisement
Annual Meeting, CHEST 2026

Presentations to examine potential role of new medications in OSA treatment

The treatment landscape for OSA is evolving rapidly, moving beyond a one-size-fits-all approach toward therapies tailored to the underlying drivers of disease. As new pharmacologic strategies emerge, clinicians are being challenged to rethink traditional measures of success and consider how symptoms, physiologic burden, patient preferences, and quality of life all factor into treatment decisions.

Presenters will explore the potential role of oral medication therapy in OSA management during the CHEST 2026 session New Medications for Treatment of OSA: The SynAIRgy and LunAIRo Trials at 9:15 am MST on Tuesday, October 20, in the Phoenix Convention Center, North Building, Room 127B.

Patrick Strollo, MD, MS, FCCP
Patrick Strollo, MD, MS, FCCP

“The SynAIRgy and LunAIRo trials tested a first-in-class investigational drug, AD109, that targets neuromuscular activation during sleep, one of the endotypes that is responsible for the pathogenesis of OSA,” said Patrick Strollo, MD, MS, FCCP, chair of the session. “If approved by the FDA, AD109 will be another tool in the toolbox to treat OSA.”

Joining Dr. Strollo will be Kara Dupuy-McCauley, MD, FCCP, Pulmonary and Sleep Medicine Specialist at Mayo Clinic. They will examine findings from the landmark SynAIRgy and LunAIRo clinical trials and discuss their implications for everyday practice. Rather than focusing solely on reductions in the apnea-hypopnea index (AHI), they will explore a broader framework for evaluating treatment effectiveness and selecting the most appropriate therapy for individual patients.

“The AHI is only one metric of treatment success,” Dr. Strollo said. “New metrics such as sleep apnea-specific hypoxic burdenand sleep apnea-specific delta heart rate have been shown to have better correlation with cardiac and cerebral vascular morbidity/mortality than the AHI. In addition, patient-reported measures such as improvement in snoring significantly impact patient satisfaction and adherence with treatment.”

His opening presentation will set the stage by placing the trial results into clinical context. His presentation will help attendees understand how to interpret the benefits of aroxybutynin/atomoxetine therapy through the lens of real-world patient care. He will discuss the practical considerations clinicians may face when weighing therapeutic gains against treatment burden and patient expectations, highlighting where these emerging data may fit within an increasingly crowded treatment landscape.

Dr. Dupuy-McCauley will delve into the biologic rationale behind aroxybutynin/atomoxetine therapy, exploring how upper-airway muscle function contributes to the pathophysiology of OSA. By examining the relationship between neuromuscular control and airway stability during sleep, she will provide important insight into why a pharmacologic approach may prove effective for certain patient populations.

“Clinicians will appreciate that, as we move toward precision medicine, drugs such as AD109 may represent an option for patients who cannot tolerate PAP or who are incompletely treated with PAP to augment the success of OSA therapy,” Dr. Strollo said.